Cambrex Invests in Generic API Development and Manufacturing Capabilities at its Milan Site

October 12, 2017
Pharmaceutical Technology Editors

PTSM: Pharmaceutical Technology Sourcing and Management

PTSM: Pharmaceutical Technology Sourcing and Management-11-01-2017, Volume 12, Issue 11

Investments include the installation of development and analytical equipment to support the development of highly potent APIs as well as a new 2800-liter hydrogenator and 1500-mm diameter centrifuge for increased flexibility and capacity within the manufacturing plant.

API manufacturer, Cambrex, announced on Oct. 12, 2017 that it has invested in a number of R&D and manufacturing capabilities to support the development and production of generic APIs at its site in Paullo, Milan, Italy. The investments include the installation of development and analytical equipment to support the development of highly potent APIs (HPAPIs), as well as a new 2800-liter hydrogenator and 1500-mm diameter centrifuge, for increased flexibility and capacity within the manufacturing plant. All equipment will be installed and validated by the end of 2017.

“We have seen increased growth of activity among highly potent molecules in the past decade for use in therapeutics for cancer and other indications, and it is now becoming more appropriate in the generic API business as patents on these begin to expire,” commented Aldo Magnini, managing director, Cambrex Milan, in a press statement. “This investment is consistent with the Cambrex strategic plan to increase the company’s small-molecule development and manufacturing capabilities, ensuring our facilities continue to meet the future demands of the industry.”

This investment comes after the installation of a new pilot plant at the site in 2017, and recent announcements of expansions across other manufacturing sites, including the construction of a $24-M, 4500-square feet highly potent API manufacturing facility at its Charles City, Iowa site, which is due to open in 2019.

Source: Cambrex